PTC Therapeutics Management
Management criteria checks 4/4
PTC Therapeutics' CEO is Matt Klein, appointed in Mar 2023, has a tenure of 2.17 years. total yearly compensation is $7.41M, comprised of 11.9% salary and 88.1% bonuses, including company stock and options. directly owns 0.08% of the company’s shares, worth $2.91M. The average tenure of the management team and the board of directors is 6.4 years and 8.2 years respectively.
Key information
Matt Klein
Chief executive officer
US$7.4m
Total compensation
| CEO salary percentage | 11.90% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.08% |
| Management average tenure | 6.4yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Solid Earnings Reflect PTC Therapeutics' (NASDAQ:PTCT) Strength As A Business
May 13
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Business And Shares Still Trailing The Industry
Apr 07
2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs
Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues.PTC Therapeutics: Upside In Rare Disease Innovation
Mar 09PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Price Is Right But Growth Is Lacking After Shares Rocket 29%
Dec 03PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
Nov 29PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 09PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
Sep 12Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
May 22Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%
May 22PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$595m |
| Dec 31 2024 | US$7m | US$882k | -US$363m |
| Sep 30 2024 | n/a | n/a | -US$453m |
| Jun 30 2024 | n/a | n/a | -US$480m |
| Mar 31 2024 | n/a | n/a | -US$579m |
| Dec 31 2023 | US$9m | US$747k | -US$627m |
| Sep 30 2023 | n/a | n/a | -US$642m |
| Jun 30 2023 | n/a | n/a | -US$618m |
| Mar 31 2023 | n/a | n/a | -US$571m |
| Dec 31 2022 | US$5m | US$598k | -US$559m |
Compensation vs Market: Matt's total compensation ($USD7.41M) is about average for companies of similar size in the US market ($USD7.42M).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
CEO
Matt Klein (52 yo)
Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.2yrs | US$7.41m | 0.080% $ 2.9m | |
| Co-Founder & Independent Director | 27.3yrs | US$377.68k | 0.019% $ 695.4k | |
| Chief Financial Officer | 1.8yrs | US$2.23m | 0.026% $ 960.5k | |
| Chief Technical Operations Officer | 6.4yrs | US$2.32m | 0.073% $ 2.7m | |
| Chief Business Officer | 10.1yrs | US$2.40m | 0.025% $ 910.6k | |
| Executive VP & Chief Medical Officer | 5yrs | US$2.25m | 0.034% $ 1.2m | |
| Senior VP | 7.9yrs | US$1.70m | 0.034% $ 1.2m | |
| Senior VP & Chief Information Officer | less than a year | no data | no data | |
| Executive VP & Chief Legal Officer | 13.2yrs | US$2.19m | 0.13% $ 4.8m | |
| Vice President of Corporate Communications | no data | no data | no data | |
| Chief Human Resources Officer | 4.6yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs | 10.3yrs | no data | no data |
Experienced Management: PTCT's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.2yrs | US$7.41m | 0.080% $ 2.9m | |
| Co-Founder & Independent Director | 27.3yrs | US$377.68k | 0.019% $ 695.4k | |
| Independent Chairman of the Board | 23.8yrs | US$551.02k | 1.91% $ 69.5m | |
| Independent Director | 19.4yrs | US$317.18k | 0.018% $ 667.0k | |
| Independent Director | 12.7yrs | US$294.18k | 0.018% $ 667.0k | |
| Independent Director | 6.4yrs | US$330.18k | 0.014% $ 515.3k | |
| Independent Director | 9.9yrs | US$306.01k | 0.018% $ 667.0k | |
| Independent Director | 2.9yrs | US$313.68k | 0.015% $ 552.1k | |
| Independent Director | 6.4yrs | US$302.18k | 0.0061% $ 223.9k | |
| Independent Director | 3.9yrs | US$309.68k | 0.017% $ 635.6k |
Experienced Board: PTCT's board of directors are considered experienced (8.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 12:01 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PTC Therapeutics, Inc. is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Geoffrey Meacham | Barclays |
| Huidong Wang | Barclays |